Wegovy Maker Wants Japan to Know It Has an Obesity Problem Too.

Novo Nordisk, a Danish drugmaker, has chosen Japan as the market to introduce its weight-loss drug, Wegovy, in Asia. Despite the perception that obesity is not a significant issue in Japan, the number of obese Japanese men has doubled in the past three decades. The market for weight-loss drugs is growing globally, and Novo Nordisk's shares have increased by 70% in the past year. The Japanese government is concerned about the improper use of the drug due to the country's strong diet culture, so the launch of Wegovy will be measured. [Extracted from the article]